bismuth-subsalicylate and Liver-Cirrhosis

bismuth-subsalicylate has been researched along with Liver-Cirrhosis* in 1 studies

Other Studies

1 other study(ies) available for bismuth-subsalicylate and Liver-Cirrhosis

ArticleYear
Bismuth Subsalicylate Coagulopathy in a Patient with Chronic Liver Disease.
    Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2019, Volume: 15, Issue:3

    Bismuth subsalicylate (BSS) is the active ingredient in over-the-counter antacid and antidiarrheal medications. Coagulopathy in the setting of acetylsalicylic acid toxicity is well documented but not in setting of bismuth subsalicylate overuse. We present a case report of coagulopathy from BSS poisoning in a patient with underlying cirrhosis. The patient's high prothrombin time suggests inhibition of vitamin K-dependent coagulation factors. The patient had decreased factor V activity, which is responsible for converting prothrombin to thrombin. Patients with cirrhosis often have hypoprothrombinemia which may be exacerbated by salicylate-induced coagulopathy. Given the widespread use of BSS products, physicians should recognize coagulopathy as a possible manifestation of toxicity especially in patients with underlying liver disease.

    Topics: Bismuth; Blood Coagulation Disorders; Chronic Disease; Female; Humans; International Normalized Ratio; Liver Cirrhosis; Middle Aged; Organometallic Compounds; Salicylates

2019